Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate.

Dorshow RB, Bugaj JE.

Regul Toxicol Pharmacol. 2019 Jul 2;107:104417. doi: 10.1016/j.yrtph.2019.104417. [Epub ahead of print]

PMID:
31276731
2.

Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate.

Bugaj JE, Dorshow RB.

Regul Toxicol Pharmacol. 2015 Jun;72(1):26-38. doi: 10.1016/j.yrtph.2015.02.018. Epub 2015 Feb 26.

PMID:
25728979
3.

18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.

McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC.

Clin Cancer Res. 2011 May 15;17(10):3332-40. doi: 10.1158/1078-0432.CCR-10-2274. Epub 2011 Jan 21.

4.

Novel approach in radionuclide tumor therapy: dose enhancement by high Z-element contrast agents.

Aziz EF, Bugaj JE, Caglar G, Dinkelborg LM, Lawaczeck R.

Cancer Biother Radiopharm. 2006 Jun;21(3):181-93.

PMID:
16918294
5.

Dose enhancement through combining internalizing radiation and contrast media.

Dinkelborg LM, Bugaj JE.

Cancer Biother Radiopharm. 2006 Jun;21(3):173-4. No abstract available.

PMID:
16918292
6.

Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.

Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL.

J Med Chem. 2003 Jul 17;46(15):3403-11.

PMID:
12852770
7.

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.

Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.

J Nucl Med. 2002 Dec;43(12):1650-6.

8.

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.

Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ.

Bioconjug Chem. 2002 Jul-Aug;13(4):721-8.

PMID:
12121126
9.

Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.

Achilefu S, Jimenez HN, Dorshow RB, Bugaj JE, Webb EG, Wilhelm RR, Rajagopalan R, Johler J, Erion JL.

J Med Chem. 2002 May 9;45(10):2003-15.

PMID:
11985468
10.

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ.

Int J Cancer. 2001 Dec 15;94(6):873-7.

11.

Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform.

Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R.

J Biomed Opt. 2001 Apr;6(2):122-33.

PMID:
11375721
12.

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP.

Int J Cancer. 2001 Jun 1;92(5):628-33.

13.

Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats.

Bugaj JE, Erion JL, Johnson MA, Schmidt MA, Srinivasan A.

Nucl Med Biol. 2001 Apr;28(3):327-34.

PMID:
11323245
14.

Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging.

Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R.

Invest Radiol. 2000 Aug;35(8):479-85.

PMID:
10946975
15.

Stabilization of the optical tracer agent indocyanine green using noncovalent interactions.

Rajagopalan R, Uetrecht P, Bugaj JE, Achilefu SA, Dorshow RB.

Photochem Photobiol. 2000 Mar;71(3):347-50.

PMID:
10732454
16.

Noninvasive fluorescence detection of hepatic and renal function.

Dorshow RB, Bugaj JE, Burleigh BD, Duncan JR, Johnson MA, Jones WB.

J Biomed Opt. 1998 Jul;3(3):340-5.

PMID:
23015088
17.

Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo.

Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, Schmidt MA, Bugaj JE.

Eur J Nucl Med. 1998 May;25(5):481-90.

PMID:
9575243
18.

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE, M├Ącke HR, Krenning EP.

Cancer Res. 1998 Feb 1;58(3):437-41.

19.

The effect of DMSO treatment on the performance of [99mTc]HEDP.

Bugaj JE, Esser PD, Tofe AJ, Borgia AT, Fawwaz RA.

Int J Nucl Med Biol. 1984;11(2):109-11.

PMID:
6434460

Supplemental Content

Loading ...
Support Center